Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

ompany is recruiting subjects in EPIC, a randomized, double-blind, placebo-controlled phase 3 study of ANX-188 in patients with sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing of completion and announcement of results of the TQT study. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and expectations indicated by the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the potential for delays in the commencement or completion of clinical studies, including as a result of difficulties with opening trial sites or enrolling study subjects or being subject to a "clinical hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; ADVENTRX's reliance on contract research organizations (CROs) to conduct its clinical studies and on other third parties to assist with important aspects of its development and regulatory activities for ANX-188 and the potential for such third parties to fail to perform as expected or required; the risk that clinical studies, including EPIC and the TQT study, are not successfully executed and/or do not successfully demonstrate the safety or efficacy of the investigational drug; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; the risk that even if clinical studies of an investigational drug in one indication are successful, cl
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  US-Australian drug discovery company, ... today confirmed its comprehensive scientific review has identified ... in areas of unmet patient need. Novogen is ... preclinical projects prior to entering into Phase 1 ... Acting Chief Executive Officer, Iain Ross ...
(Date:8/31/2015)... 2015 Trimb Healthcare AB ("Trimb") today announced ... Group BV ("YouMedical"), a Dutch OTC company with operations ... of approximately EUR 16 million, with solid growth and ... ambition is to build a leading international OTC company, ... goal. YouMedical gives us a stronger North European OTC ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Proove Biosciences, ... County Technology Alliance Annual High Tech Awards. , Now in its 22nd year, ... products which drive innovation here, across the nation and around the world. The OC ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove ... at the International Spine Intervention Society’ s 23rd Annual Scientific Meeting ... 1st, 2015. With a focus on evidence-based research and clinical application, the event ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... SAN JOSE, Calif., April 4, 2011 Researchers ... Institute of Bioengineering and Nanotechnology have made a ... were shown to physically detect and destroy antibiotic-resistant ... known as MRSA, while leaving healthy cells unharmed. ...
... TORONTO, April 4, 2011 Generex Biotechnology ... today the publication of a report comparing ... peptide vaccines designed for immunotherapy of breast ... developed by the Company,s wholly-owned subsidiary, Antigen ...
... CryoLife, Inc. (NYSE: CRY ), an implantable biological ... it has filed an IDE with the United ... for the purpose of obtaining Pre-Market Approval (PMA) to distribute ... or following traumatic injuries. PerClot is a ...
Cached Biology Technology:IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 2IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 3IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment 4Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 2Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 3Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research 4CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... available to health officials and businesses, a Purdue University ... of melamine in infant formula. Using infrared lasers ... of food science, was able to detect melamine in ... five minutes or less. Melamine, a synthetic chemical used ...
... Mittermeier, the president of Conservation International and a global ... Peterson Medal from the Harvard Museum of Natural History. ... strategist who has written more than 500 scientific and ... He has described 11 species new to science, had ...
... cancer researchers at The Ohio State University has ... certain proteins that may make good biomarkers in ... liquid chromatography-mass spectrometry (LC-MS) can measure variations in ... and store DNA. The technology accurately detected differences ...
Cached Biology News:Researcher: Lasers used to detect melamine in baby formula 2Study validates means to measure possible leukemia marker 2
... The Captivate magnetic ... can be used in conjunction ... (C-21473, C-21474, C-21476) or other ... with most 96-well microplates. Cell ...
Protein Phosphorylation...
...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Biology Products: